Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$172.78 USD

172.78
7,916,712

-1.04 (-0.60%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $173.01 +0.23 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VYM

Zacks Equity Research

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWX

Zacks Equity Research

Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $178.19, marking a +0.87% move from the previous day.

Zacks Equity Research

The Zacks Analyst Blog Highlights Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy

by Zacks Equity Research

Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy are included in this Analyst Blog.

Zacks Equity Research

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Sheraz Mian headshot

Earnings Outlook for 2023 and Featured Reports for Apple, JNJ, & Others

by Sheraz Mian

Today's Research Daily an earnings update and features new research reports on Apple (AAPL), JNJ (JNJ), CSX (CSX) & Others.

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $176.66 in the latest trading session, marking a -0.43% move from the prior day.

Zacks Equity Research

Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPYV

Zacks Equity Research

Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment

by Zacks Equity Research

Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.

Zacks Equity Research

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

by Zacks Equity Research

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

Zacks Equity Research

Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PFM

Zacks Equity Research

Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for OUSA

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Moves -0.11%: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $175.48, marking a -0.11% move from the previous day.

Zacks Equity Research

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

by Zacks Equity Research

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.

Zacks Equity Research

Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca

by Zacks Equity Research

Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

4 Large Drug Stocks to Watch in a Booming Industry

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $177.84, moving +1.19% from the previous trading session.

Andrew Rocco headshot

The Return of "Merger Monday"

by Andrew Rocco

Two major deals in the biotech and software industry were inked this weekend.

Zacks Equity Research

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Neena Mishra headshot

ETF Investing Strategies for 2023

by Neena Mishra

We discuss the market outlook and investing strategies for 2023.

Zacks Equity Research

Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VIG

Zacks Equity Research

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $176.10, moving -1.5% from the previous trading session.

Zacks Equity Research

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $178 in the latest trading session, marking a +1.08% move from the prior day.